Abstract：
Upper lateral hip pain is a common complaint in adults and is referred to as greater trochanteric pain syndrome (GTPS) and is more prevalent among older women. This is a debilitating condition that could result in lower physical activity and quality of life, and higher unemployment rate. GTPS is a clinical diagnosis, and many cases improve with conservative medical management (CMM). However, there is still a gap between patients not responding to CMM and those who are not good surgical candidates. Thus, percutaneous ultrasound tenotomy (PUT) may be a valuable treatment option to limit this gap.
Demonstration of the one-year pain and functional outcomes, including sit to stand.
Academic tertiary care medical center.
Forty-eight consecutive patients with refractory trochanteric pain due to iliotibial band (ITB) tendinopathy. Fifty-six hips were treated; 8 patients underwent bilateral procedures. Electronic medical record review of consecutive patients who underwent ITB TENEX® was performed at Montefiore Medical Center from December 2019 to December 2021. Institutional guidelines recommended TENEX® for greater trochanteric pain refractory to conservative treatment and ultrasound (US) confirmed ITB tendinopathy (hypoechogenicity or thickened tendon > 6 mm). Pain level, as well as sit-to-stand, side-lying, and walking tolerance levels were evaluated at baseline preprocedure visit and one-year visit. Follow-up was performed by independent practitioners and corroborated by chart review.
Numeric Rating Scale (NRS-11) improved by 4 points across all patients. Seventy percent of patients endorsed pain relief at one-year visit. Median preprocedure NRS-11 was 9. The reported median NRS-11at one year was 5 (Wilcoxon signed rank NRS-11 demonstrated a Z score of -6.042 with P < 0.001). One-year analysis among all patients revealed 57%, 78%, and 66% improvement in side-lying, sit-to-stand, and walking tolerance levels, respectively.
We believe that our results must be confirmed with a randomized control trial with a control arm and more patients included.
PUT of the ITB using the TENEX® tissue remodeling device could be a safe and effective treatment for ITB tendinopathy-associated GTPS.
Demonstration of the one-year pain and functional outcomes, including sit to stand.
Academic tertiary care medical center.
Forty-eight consecutive patients with refractory trochanteric pain due to iliotibial band (ITB) tendinopathy. Fifty-six hips were treated; 8 patients underwent bilateral procedures. Electronic medical record review of consecutive patients who underwent ITB TENEX® was performed at Montefiore Medical Center from December 2019 to December 2021. Institutional guidelines recommended TENEX® for greater trochanteric pain refractory to conservative treatment and ultrasound (US) confirmed ITB tendinopathy (hypoechogenicity or thickened tendon > 6 mm). Pain level, as well as sit-to-stand, side-lying, and walking tolerance levels were evaluated at baseline preprocedure visit and one-year visit. Follow-up was performed by independent practitioners and corroborated by chart review.
Numeric Rating Scale (NRS-11) improved by 4 points across all patients. Seventy percent of patients endorsed pain relief at one-year visit. Median preprocedure NRS-11 was 9. The reported median NRS-11at one year was 5 (Wilcoxon signed rank NRS-11 demonstrated a Z score of -6.042 with P < 0.001). One-year analysis among all patients revealed 57%, 78%, and 66% improvement in side-lying, sit-to-stand, and walking tolerance levels, respectively.
We believe that our results must be confirmed with a randomized control trial with a control arm and more patients included.
PUT of the ITB using the TENEX® tissue remodeling device could be a safe and effective treatment for ITB tendinopathy-associated GTPS.
摘要：
上外侧髋关节疼痛是成人常见的主诉，被称为大转子疼痛综合征（GTPS），在老年妇女中更为普遍。这是一种使人衰弱的状况，可能导致身体活动和生活质量下降，和更高的失业率。GTP是一种临床诊断,许多病例通过保守医疗管理（CMM）改善。然而,对CMM无反应的患者与不适合手术的患者之间仍存在差距.因此，经皮超声肌腱切开术(PUT)可能是限制这一差距的有价值的治疗选择.
显示一年的疼痛和功能结果，包括坐着站着。
学术三级护理医疗中心。
48例连续患者因髂胫带（ITB）肌腱病引起的难治性股骨粗隆痛。56髋接受了治疗；8例患者接受了双侧手术。2019年12月至2021年12月，在蒙特菲奥雷医疗中心对接受ITBTENEX®治疗的连续患者进行了电子病历审查。机构指南建议TENEX®用于保守治疗难以治疗的大转子疼痛，超声（US）证实ITB肌腱病（回声减退或肌腱增厚>6mm）。疼痛程度,以及坐着站着，侧卧,在基线术前访视和1年访视时评估行走耐受水平.随访由独立从业人员进行，并通过图表审查证实。
数字评定量表（NRS-11）在所有患者中提高了4分。70％的患者在一年的访问中认可疼痛缓解。术前NRS-11中位数为9。一年报告的NRS-11中位数为5（Wilcoxon签名等级NRS-11显示Z评分为-6.042，P<0.001）。在所有患者中进行的为期一年的分析显示57％，78%,侧卧改善66%，坐到站，和行走耐受水平，分别。
我们认为，我们的结果必须通过一项具有对照臂的随机对照试验得到证实，并包括更多的患者。
使用TENEX®组织重塑装置对ITB进行PUT可以安全有效地治疗与ITB肌腱病相关的GTP。
显示一年的疼痛和功能结果，包括坐着站着。
学术三级护理医疗中心。
48例连续患者因髂胫带（ITB）肌腱病引起的难治性股骨粗隆痛。56髋接受了治疗；8例患者接受了双侧手术。2019年12月至2021年12月，在蒙特菲奥雷医疗中心对接受ITBTENEX®治疗的连续患者进行了电子病历审查。机构指南建议TENEX®用于保守治疗难以治疗的大转子疼痛，超声（US）证实ITB肌腱病（回声减退或肌腱增厚>6mm）。疼痛程度,以及坐着站着，侧卧,在基线术前访视和1年访视时评估行走耐受水平.随访由独立从业人员进行，并通过图表审查证实。
数字评定量表（NRS-11）在所有患者中提高了4分。70％的患者在一年的访问中认可疼痛缓解。术前NRS-11中位数为9。一年报告的NRS-11中位数为5（Wilcoxon签名等级NRS-11显示Z评分为-6.042，P<0.001）。在所有患者中进行的为期一年的分析显示57％，78%,侧卧改善66%，坐到站，和行走耐受水平，分别。
我们认为，我们的结果必须通过一项具有对照臂的随机对照试验得到证实，并包括更多的患者。
使用TENEX®组织重塑装置对ITB进行PUT可以安全有效地治疗与ITB肌腱病相关的GTP。
